Document:

Second Amendment to Credit Agreement

  
 Exhibit 10.2

 SECOND AMENDMENT TO CREDIT AGREEMENT 

THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of this
16th day of December, 2003, among PSS World Medical,
Inc., a Florida corporation (“PSS”), Gulf South Medical Supply, Inc., a Delaware corporation (“Gulf South”), and Physician Sales & Services Limited Partnership, a Florida limited
partnership (“PSS LP”); PSS, Gulf South and PSS LP are referred to hereinafter each individually as a “Borrower” and collectively as “Borrowers”), PSS Holding, Inc., a Florida corporation
(“PSS Holding”), PSS Service, Inc., a Florida corporation (“PSS Service”), Physician Sales & Service, Inc., a Florida corporation (“Physician Sales & Service”),
Highpoint Holdings, Inc., a Nevada corporation (“Highpoint”), Highpoint Healthcare Distribution, Inc., a Nevada corporation (“Highpoint Healthcare”), Gulf South Reimbursement Services, Inc., a
Florida corporation (“Gulf South Reimbursement”), RBG Holdings, Inc., a Tennessee corporation (“RGB”), ProClaim, Inc., a Tennessee corporation (“ProClaim”), Ancillary Management
Solutions, Inc., a Tennessee corporation (“Ancillary”), and ThriftyMed, Inc., a Florida corporation (“ThriftyMed”; PSS Holding, PSS Service, Physician Sales & Service, Highpoint, Highpoint
Healthcare, Gulf South Reimbursement, RBG, ProClaim, Ancillary and ThriftyMed are referred to hereinafter each individually as a “Guarantor” and collectively as “Guarantors”), the Lenders party to this Amendment
(the “Lenders”), and Bank of America, N.A., as Agent for the Lenders (the “Agent”). 
 W I T
N E S S E T H : 
 WHEREAS, Borrowers, Guarantors, the Lenders and the Agent entered into that certain Credit Agreement,
dated as of May 20, 2003, pursuant to which the Lenders agreed to make certain loans to Borrowers (as amended, modified, supplemented and restated from time to time, the “Credit Agreement”); and 

WHEREAS, Borrowers, Guarantors, the Lenders and the Agent desire to enter into this Amendment for the purpose of amending the Credit
Agreement in certain respects. 
 NOW, THEREFORE, in consideration of the foregoing premises, and other good and valuable
consideration, the receipt and legal sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1. All capitalized terms used herein and not otherwise expressly defined herein shall have the respective meanings given to such
terms in the Credit Agreement. 
 2. The Credit Agreement is amended by deleting the definition of “Applicable
Margin” and replacing it with the following in lieu thereof: 
 “Applicable Margin” means 

 (i) with respect to Base Rate Loans and all other Obligations (other than LIBOR Loans), 0.25%; and

 (ii) with respect to LIBOR Loans, 2.25%. 

  
 The Applicable Margins
shall be adjusted (up or down) prospectively on a quarterly basis as determined by the Leverage Ratio, commencing with the first day of the first calendar month that occurs more than 5 days after delivery of the Borrowers’ quarterly Financial
Statements to Lenders for the fiscal quarter ending September 26, 2003. Adjustments in Applicable Margins shall be determined by reference to the following grids: 
  

			
	 If the Ratio of Adjusted Funded Debt to EBITDA is:
	  	 Level of Applicable Margins:

	> 3.5 to 1.0	  	Level I
	> 3.0 to 1.0 but ‹ 3.5 to 1.0	  	Level II
	> 2.5 to 1.0 but ‹ 3.0 to 1.0	  	Level III
	> 2.0 to 1.0 but ‹ 2.5 to 1.0	  	Level IV
	> 1.50 to 1.0 but ‹ 2.0 to 1.0	  	Level V
	> 1.25 to 1.0 but ‹ 1.5 to 1.0	  	Level VI
	< 1.25 to 1.0	  	Level VII

  

																													
	 	  	Applicable Margins	 
	 	  	Level I	 	 	Level II	 	 	Level III	 	 	Level IV	 	 	Level V	 	 	Level VI	 	 	Level VII	 
	 Base Rate Loans
	  	 	1.00	% 	 	 	0.75	% 	 	 	0.50	% 	 	 	0.25	% 	 	 	0.00	% 	 	 	0.00	% 	 	 	(0.25	%) 
	 LIBOR Loans
	  	 	3.00	% 	 	 	2.75	% 	 	 	2.50	% 	 	 	2.25	% 	 	 	2.00	% 	 	 	1.75	% 	 	 	1.75	% 

 All adjustments in the
Applicable Margins after the adjustments with respect to the fiscal quarter ending September 26, 2003 shall be implemented quarterly on a prospective basis, for each calendar month commencing at least 5 days after the date of delivery to the
Lenders of quarterly unaudited or annual audited (as applicable) Financial Statements evidencing the need for an adjustment. Concurrently with the delivery of those Financial Statements, the Borrowers shall deliver to the Agent and the Lenders a
certificate, signed by a Designated Financial Officer, setting forth in reasonable detail the basis for the continuance of, or any change in, the Applicable Margins. In the event that, subsequent to the setting of the Applicable Margins based on the
Borrowers’ unaudited Financial Statements as of the end of the last fiscal quarter of any Fiscal Year, the Borrowers deliver their audited Financial Statements as of the end of such Fiscal Year and such audited Financial Statements call for a
higher level set forth in the foregoing grid, such higher level shall apply retroactively to the date of the setting of the Applicable Margins based on such unaudited Financial Statements. Failure to timely deliver such Financial Statements shall,
at the election of the Agent and in addition to any other remedy provided for in the Agreement, result in an increase in the Applicable Margins to the highest level set forth in the foregoing grid, until the first day of the first calendar month
following the delivery of those Financial Statements demonstrating that such an increase is not required. If a Default or Event of Default has occurred and is continuing at the time any reduction in the Applicable Margins is to be implemented, no
reduction may occur until the first day of the first calendar month following the date on which such Default or Event of Default is waived or cured. 
 3. The Credit Agreement is amended by deleting the definition of “Maximum Inventory Loan Amount” and replacing it with the following in lieu thereof: 

“Maximum Inventory Loan Amount” means $90,000,000.  

4. The Credit Agreement is amended by deleting the definition of “Maximum Revolver Amount” and replacing it with
the following in lieu thereof: 
 “Maximum Revolver Amount” means $200,000,000.  

5. The Credit Agreement is amended by deleting the definition of “Permitted Acquisition” and replacing it with the
following in lieu thereof: 
 “Permitted Acquisition” means the acquisition by an Obligor of all or a
substantial portion of the assets or equity interests of another Person in the same or a similar line of business to that conducted by the Obligors (the 

 
“Target”) so long as: (a) the Obligors shall provide the Agent notice of the proposed Acquisition, and such pro forma and historical financial statements and other information and
documents relating to the proposed Acquisition as the Agent may request, at least 15 days prior to the date of the consummation of the proposed Acquisition; (b) the purchase price for such acquisition does not exceed $10,000,000 individually or
$50,000,000 in the aggregate for all such acquisitions (it being understood that (i) purchase price shall include all cash paid at closing, all Debt described in Section 7.13(f), and all other purchase price consideration (other
than good faith “earn out” consideration not intended as a substitute for cash consideration to circumvent the limitations contained in this definition) in connection with such acquisition, and (ii) such $50,000,000 aggregate amount
shall be calculated by adding the purchase price from all acquisitions consummating on or after May 20, 2003 through and including the Termination Date); (c) no Default or Event of Default exists before or after giving effect to such
acquisition; (d) after giving effect to the consummation of such acquisition (including any Loans made hereunder to finance such acquisition), Excess Availability is greater than $20,000,000; provided, that no assets of the Target shall be
included in the calculation of Excess Availability for purposes of this clause (d) or otherwise until the Agent has completed a satisfactory field examination with respect to the Target and its assets (it being understood that,
notwithstanding the completion of a satisfactory field examination, the Agent shall have the right, in its reasonable commercial discretion, to establish lower advance rates and/or reserves against the Accounts and Inventory of the Target and/or to
elect not to include any such Accounts or Inventory as Eligible Accounts or Eligible Inventory); (e) after giving effect to the consummation of such Acquisition, the Borrowers are in compliance with the financial covenants set forth in
Section 7.23 on a pro forma basis (it being understood that this requirement shall apply whether or not Excess Availability is greater than $25,000,000 after giving effect to the consummation of such Acquisition); provided, that such
financial covenants shall be measured as of the most recently ended fiscal month for which the Borrowers have delivered the financial statements required under Section 5.2(b) or (c), as the case may be, for the twelve fiscal month
period then ended; (f) the Accounts Payable Turnover, calculated as of the date of such proposed Acquisition and as of the most recently ended fiscal month for which the Borrowers have delivered the financial statements required under
Section 5.2(b) or (c), as the case may be, shall not in either case exceed 45 days; (g) such acquisition does not involve a “hostile” takeover or tender offer; (h) a Responsible Officer delivers to the Agent a
certificate (i) demonstrating compliance with clauses (d), (e) and (f) above, and (ii) stating that no Default or Event of Default exists before or after giving effect to such acquisition; (i) after
giving effect to the consummation of such acquisition (including any Loans made hereunder to finance such acquisition) the Aggregate Revolver Outstandings shall not exceed the Maximum Revolver Amount minus $20,000,000; and (j) if the Target
will become a Subsidiary of a Borrower in connection with such acquisition, the Borrowers and the Target shall cause the Target to become a Borrower (or, if the Agent requires, a Guarantor) hereunder and grant to the Agent, for the benefit of the
Agent and the Lenders, a perfected, first-priority Lien on substantially all of the assets of the Target, all pursuant to documentation in form and substance acceptable to the Agent in its discretion. 

6. The Credit Agreement is amended by deleting Schedule 1.1 and replacing it with the Schedule 1.1 attached hereto.

 7. The effectiveness of this Amendment is expressly conditioned upon the following: 

(a) the due execution and delivery of this Amendment by each of the parties hereto; 

(b) the delivery to the Agent of duly executed originals of each of the documents set forth on the Closing Checklist,
a copy of which is attached hereto as Exhibit A; and 
 (c) the payment by the Borrowers of the
amendment fee described in the fee letter with the Agent. 
 8. To induce the Agent and the Lenders to enter into this
Amendment, Borrowers and Guarantors hereby represent and warrant that, as of the date hereof, there exists no Default or Event of Default under the Credit Agreement. 

  
 9. Borrowers and
Guarantors hereby restate, ratify, and reaffirm each and every term, condition, representation and warranty heretofore made by each of them under or in connection with the execution and delivery of the Credit Agreement, as modified hereby, and the
other Loan Documents, as fully as though such representations and warranties had been made on the date hereof and with specific reference to this Amendment, except to the extent that any such representation or warranty relates solely to a prior
date. 
 10. Except as expressly set forth herein, the Credit Agreement and the other Loan Documents shall be and remain in
full force and effect as originally written, and shall constitute the legal, valid, binding and enforceable obligations of Borrowers and Guarantors to the Agent and the Lenders. 

11. Borrowers agree to pay on demand all reasonable costs and expenses of the Agent in connection with the preparation, execution,
delivery and enforcement of this Amendment and all other Loan Documents and any other transactions contemplated hereby, including, without limitation, the reasonable fees and out-of-pocket expenses of legal counsel to the Agent. 

12. Borrowers and Guarantors agree to take such further action as the Agent shall reasonably request in connection herewith to
evidence the agreements herein contained. 
 13. This Amendment may be executed in any number of counterparts and by
different parties hereto in separate counterparts, each of which, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. 

14. This Amendment shall be binding upon and inure to the benefit of the successors and permitted assigns, and legal representatives
and heirs, of the parties hereto. 
 15. This Amendment shall be governed by, and construed in accordance with, the laws of
the State of Georgia. 

  
 IN WITNESS WHEREOF,
Borrowers, Guarantors, the Agent and the Lenders have caused this Amendment to be duly executed as of the date first above written. 
  

			
	BORROWERS:
	
	PSS WORLD MEDICAL, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	GULF SOUTH MEDICAL SUPPLY, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	PHYSICIAN SALES & SERVICE LIMITED PARTNERSHIP
		
	By:	 	 PSS World Medical, Inc.,
 Its
general partner

		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	GUARANTORS:
	
	PSS HOLDING, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	PSS SERVICE, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	PHYSICIAN SALES & SERVICE, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President

  
 
			
	THRIFTYMED, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	HIGHPOINT HOLDINGS, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	HIGHPOINT HEALTHCARE DISTRIBUTIONS, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	GULF SOUTH REIMBURSEMENT SERVICES, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	RBG HOLDINGS, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	PROCLAIM, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President
	
	ANCILLARY MANAGEMENT SOLUTIONS, INC.
		
	By:	 	/s/ David D. Klarner
	Name:	 	David D. Klarner
	Title:	 	Vice President

 [Signatures Continued
on Next Page] 

  
 
			
	LENDERS:
	
	BANK OF AMERICA, N.A.
		
	By:	 	/s/ Mark Herdman
	Name:	 	Mark Herdman
	Title:	 	Vice President
	
	GENERAL ELECTRIC CAPITAL CORPORATION
		
	By:	 	/s/ Steven Wagnblas
	Name:	 	Steven Wagnblas
	Title:	 	Duly Authorized Signatory
	
	FLEET CAPITAL CORPORATION
		
	By:	 	/s/ W. Reed Paden
	Name:	 	W. Reed Paden
	Title:	 	Vice President
	
	WACHOVIA BANK, N.A.
		
	By:	 	/s/ Eric Butler
	Name:	 	Eric Butler
	Title:	 	Managing Director
	
	AGENT:
	
	BANK OF AMERICA, N.A.
		
	By:	 	/s/ Mark Herdman
	Name:	 	Mark Herdman
	Title:	 	Vice President

  
 SCHEDULE 1.1

 COMMITMENTS 
  

									
	 Lender
	  	Commitment	 	  	Pro Rata Share	 
	 Bank of America, N.A
	  	$	83,000,000	  	  	 	41.500	% 
	 General Electric Capital Corporation
	  	$	47,000,000	  	  	 	23.500	% 
	 Fleet Capital Corporation
	  	$	35,000,000	  	  	 	17.500	% 
	 Wachovia Bank, N.A
	  	$	35,000,000	  	  	 	17.500	% 

  
 Exhibit A

 CLOSING CHECKLIST 
 Second Amendment 
 relating to 

Amended and Restated Credit Agreement dated May 20, 2003 among PSS World Medical, Inc. and the other 

borrowers listed on Appendix 1 
 (“Borrowers”) 
 and 

The Guarantors listed on Appendix 1 
 (“Guarantors”) 
 and 

A syndicate of lenders party thereto (the “Lenders”) 

and 

Bank of America, N.A., as agent for the Lenders 
 (“Agent”) 
 December     , 2003

  
  

 

					
	 Party
Responsible
	  	 Document

	 This document contains AUTO NUMBERING

			
	TS	  	1.	  	Preliminary Lien Searches (See Appendix 2)
			
	TS	  	2.	  	Second Amendment
			
	TS/B	  	3.	  	Bringdown Secretary’s Certificate for PSS World Medical, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	4.	  	Bringdown Certificate for Physician Sales & Service Limited Partnership, including Exhibit A – Good Standing Certificate
			
	TS/B	  	5.	  	Bringdown Secretary’s Certificate for Gulf South Medical Supply, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	6.	  	Bringdown Secretary’s Certificate for Physician Sales & Services, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	7.	  	Bringdown Secretary’s Certificate for PSS Holding, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	8.	  	Bringdown Secretary’s Certificate for PSS Service, Inc., including Exhibit A – Good Standing Certificate

  

					
	TS/B	  	9.	  	Bringdown Secretary’s Certificate for ThriftyMed, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	10.	  	Bringdown Secretary’s Certificate for Highpoint Holdings, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	11.	  	Bringdown Secretary’s Certificate for Highpoint Healthcare Distribution, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	12.	  	Bringdown Secretary’s Certificate for Gulf South Reimbursement Services, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	13.	  	Bringdown Secretary’s Certificate for RBG Holdings, Inc., including Exhibit A – Good Standing Certificate
			
	TS/B	  	14.	  	Bringdown Secretary’s Certificate for ProClaim, Inc., including Exhibit A – Good Standing Certificate:
			
	TS/B	  	15.	  	Bringdown Secretary’s Certificate for Ancillary Management Solutions, Inc., including Exhibit A – Good Standing Certificate:
			
	BC	  	16.	  	 Opinion of Counsel

 TS = Troutman Sanders LLP (counsel to BA) 
 BA = Bank of America, N.A. 

B = PSS World Medical, Inc. and the other Borrowers listed on Appendix 1 
 BC = Foley & Lardner 

  
 Appendix 1

 Borrowers 

PSS World Medical, Inc. 
 Physician
Sales & Service Limited Partnership 
 Gulf South Medical Supply, Inc. 
 Guarantors 
 Physician Sales & Services, Inc. 

PSS Holding, Inc. 
 PSS Service, Inc. 

ThriftyMed, Inc. 
 Highpoint Holdings, Inc.

 Highpoint Healthcare Distribution, Inc. 
 Gulf South Reimbursement Services, Inc. 
 RBG Holdings, Inc. 

ProClaim, Inc. 
 Ancillary Management Solutions,
Inc. 

  
 Appendix 2

 Preliminary Lien Search Locations 
 Names (Full Searches): 
 PSS World Medical, Inc. 

Physician Sales & Service Limited Partnership 
 Gulf South Medical Supply, Inc. 
 Locations: 

[state of organization and chief executive office]Purchase Agreement

  
 Exhibit 10.3

 EXECUTION VERSION 
 PSS World Medical, Inc. 
 3.125% Convertible Senior Notes due
August 1, 2014 
  
  

Purchase Agreement 
 July 29, 2008 
 Goldman, Sachs & Co., 

85 Broad Street, 
 New York, New York 10004

 Ladies and Gentlemen: 
 PSS World
Medical, Inc., a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman, Sachs & Co. (the “Purchaser”) an aggregate of $200,000,000 principal amount
of the Convertible Senior Notes due August 1, 2014, convertible into common stock, par value $0.01 (“Stock”), of the Company, specified above (the “Firm Securities”) and, at the election of the Purchaser, up to an aggregate
of $30,000,000 additional aggregate principal amount (the “Optional Securities”) (the Firm Securities and the Optional Securities which the Purchaser elects to purchase pursuant to Section 2 hereof are herein collectively called the
“Securities”). In connection with the offering of the Securities, the Company is entering into convertible note hedge and warrant transactions with Goldman, Sachs & Co. (the “Convertible Note Hedge and Warrant
Counterparty”) pursuant to confirmation letters, dated July 29, 2008, subject to an agreement in the form of the ISDA 2002 Master Agreement (collectively, the “Convertible Note Hedge and Warrant Transaction Documentation”, and
the confirmation letter relating to the convertible note hedge transaction, the “Convertible Note Hedge Confirmation” and the confirmation letter relating to the warrant transaction, the “Warrant Confirmation”). 

 

	1.	The Company represents and warrants to, and agrees with, the Purchaser that: 

 

	 	(a)	 A preliminary offering circular, dated July 28, 2008 (the “Preliminary Offering Circular”), and an offering circular, dated
July 29, 2008 (the “Offering Circular”), have been prepared in connection with the offering of the Securities and the shares of Stock issuable upon conversion thereof. The Preliminary Offering Circular, as amended and supplemented
immediately prior to the Applicable Time (as defined in Section 1(b)), is hereinafter referred to the “Pricing Circular”. Any reference to the Preliminary Offering Circular, the Pricing Circular or the Offering Circular shall be
deemed to refer to and include the Company’s most recent Annual Report on Form 10-K and all subsequent documents filed with the United States Securities and Exchange Commission (the “Commission”) pursuant to Section 13(a), 13(c),
14 or 15(d) of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”) on or prior to the date of such circular and any reference to the Preliminary Offering Circular, the Pricing Circular or the Offering
Circular, as the case may be, as amended or supplemented, as of any specified date, shall be deemed to include (i) any documents filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of
the Preliminary Offering Circular, the Pricing Circular or the Offering Circular, as the case may be, and prior to such specified date and (ii) any Additional Issuer Information (as defined in Section 5(f)) furnished by the Company prior
to the completion of the distribution of the Securities; and all documents filed under the Exchange Act and so deemed to be included in the Preliminary Offering Circular, the Pricing Circular or the Offering Circular, as the case may be, or any
amendment or supplement thereto are hereinafter called the “Exchange Act Reports”. The Exchange 

	 	 
Act Reports, when they were or are filed with the Commission, conformed or will conform in all material respects to the applicable requirements of the Exchange Act and the applicable rules and
regulations of the Commission thereunder; and no such documents were filed with the Commission since the Commission’s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this
Agreement, except as set forth on Schedule I(a) hereof. The Preliminary Offering Circular or the Offering Circular and any amendments or supplements thereto and the Exchange Act Reports did not and will not, as of their respective dates,
contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that
this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Purchaser for use therein; 

 

	 	(b)	For the purposes of this Agreement, the “Applicable Time” is 5:30 p.m. (Eastern time) on the date of this Agreement; the Pricing Circular as supplemented by
the information set forth in Schedule II hereto, taken together (collectively, the “Pricing Disclosure Package”) as of the Applicable Time, did not include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Company Supplemental Disclosure Document (as defined in Section 6(a)) listed on Schedule I(b) hereto
does not conflict with the information contained in the Pricing Circular or the Offering Circular and each such Company Supplemental Disclosure Document, as supplemented by and taken together with the Pricing Disclosure Package as of the Applicable
Time, did not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that
this representation and warranty shall not apply to statements or omissions made in a Company Supplemental Disclosure Document in reliance upon and in conformity with information furnished in writing to the Company by the Purchaser expressly for use
therein; 

  

	 	(c)	Neither the Company nor any of its subsidiaries has sustained since the date of the latest audited financial statements included or incorporated by reference in the
Pricing Circular any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as
set forth or contemplated in the Pricing Circular; and, since the respective dates as of which information is given in the Pricing Circular, there has not been any change in the capital stock or long-term debt of the Company or any of its
subsidiaries (other than stock option transactions, normal debt payments and other such transactions in the normal course of business) or any material adverse change, or any development involving a prospective material adverse change (other than
general economic and industry conditions that would not disproportionately affect the Company), in or affecting the general affairs, management, financial position, shareholders’ equity or results of operations of the Company and its
subsidiaries, otherwise than as set forth or contemplated in the Pricing Circular; 

  

	 	(d)	The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all material personal property owned
by them, in each case free and clear of all liens, encumbrances and defects except (i) as set forth in the Pricing Circular, or (ii) as do not materially affect the value of such property and do not interfere with the use made and proposed
to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not
material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries; 

  

	 	(e)	 The Company (i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Florida, with
power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Circular, and (ii) has been duly qualified as a foreign corporation for the transaction of business and is in good standing
under the laws of each other jurisdiction in which it owns or 

  
 2 

	 	 
leases properties or conducts any business so as to require such qualification, except where the failure to be so qualified or in good standing under the laws of such other jurisdiction would
not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; 

  

	 	(f)	Each subsidiary of the Company (i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of its jurisdiction of
incorporation with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Circular, and (ii) has been duly qualified as a foreign corporation for the transaction of business and is
in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except where the failure to be so qualified or in good standing under the laws of such
other jurisdiction would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; 

  

	 	(g)	Gulf South Medical Supply, Inc. is the only subsidiary of the Company that is a significant subsidiary of the Company’s within the meaning of Section 1-02(w)
of Regulation S-X under the Securities Act of 1933, as amended (the “Act”); 

  

	 	(h)	The Company has an authorized capitalization as set forth in the Pricing Circular, and all of the issued shares of capital stock of the Company have been duly and
validly authorized and issued and are fully paid and non-assessable; the shares of Stock initially issuable upon conversion of the Securities have been duly and validly authorized and reserved for issuance and, when issued and delivered in
accordance with the provisions of the Securities and the Indenture referred to below, will be duly and validly issued, fully paid and non-assessable and will conform to the description of the Stock contained in the Pricing Disclosure Package and the
Offering Circular; and all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and (except for directors’ qualifying shares) are owned
directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims except as set forth in the Pricing Circular; 

  

	 	(i)	The Securities have been duly authorized by the Company and, when issued and delivered pursuant to this Agreement, when authenticated by the Trustee in accordance with
the Indenture (as defined below), and when paid for by the Purchaser in accordance with the terms hereof, will have been duly executed, authenticated, issued and delivered and will constitute valid and legally binding obligations of the Company
entitled to the benefits provided by the indenture to be dated as of August 4, 2008 (the “Indenture”) between the Company and U.S. Bank National Association, as Trustee (the “Trustee”), under which they are to be issued and
will be convertible into Stock in accordance with their terms and the Indenture; the Securities will rank equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness; the Indenture has been duly
authorized and, when executed and delivered by the Company and the Trustee, the Indenture will constitute a valid and legally binding instrument of the Company, enforceable against the Company in accordance with its terms, subject, as to
enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (regardless of whether such enforcement is considered in a proceeding
at law or in equity); and the Securities and the Indenture will conform to the descriptions thereof in the Pricing Disclosure Package and the Offering Circular and will be in substantially the form previously delivered to you;

  

	 	(j)	This Agreement has been duly authorized, executed and delivered by the Company; 

 

	 	(k)	None of the transactions contemplated by this Agreement (including, without limitation, the use of the proceeds from the sale of the Securities) will violate or result
in a violation of Section 7 of the Exchange Act, or any regulation promulgated thereunder, including, without limitation, Regulations T, U, and X of the Board of Governors of the Federal Reserve System; 

  
 3 

  

	 	(l)	Prior to the date hereof, neither the Company nor any of its “affiliates” (as defined in Rule 144 under the Act) has taken any action that is prohibited
by Section 9(a) of the Exchange Act or any applicable state securities laws; 

  

	 	(m)	The issue and sale of the Securities and the compliance by the Company with all of the provisions of the Securities, the Indenture and this Agreement and the
consummation of the transactions herein and therein contemplated (including, without limitation, the use of proceeds from the sale of the Securities) will not conflict with or result in a breach or violation of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which
any of the property or assets of the Company or any of its subsidiaries is subject except for such conflicts, breaches or violations which would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries,
taken as a whole, nor will such action result in any violation of the provisions of the Articles of Incorporation or By-laws of the Company or any statute or any order, rule or regulation of any court or governmental agency or body having
jurisdiction over the Company or any of its subsidiaries or any of their properties; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and
sale of the Securities or the consummation by the Company of the transactions contemplated by this Agreement or the Indenture, except such consents, approvals, authorizations, registrations or qualifications as may be required under state securities
or Blue Sky laws in connection with the purchase and distribution of the Securities by the Purchaser; 

  

	 	(n)	Neither the Company nor any of its subsidiaries (i) is in violation of its Articles of Incorporation or By-laws or (ii) in default in the performance or
observance of any obligation, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except for
such defaults that would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; 

  

	 	(o)	The statements set forth in the Pricing Circular and the Offering Circular under the caption “Description of Notes” and “Description of Capital
Stock”, insofar as they purport to constitute a summary of the terms of the Securities and the Stock, under the caption “Certain United States Federal Income Tax Considerations”, and under the caption “Plan of Distribution”,
insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and complete in all material respects; 

  

	 	(p)	Other than as set forth in the Pricing Circular, there are no legal or governmental proceedings pending nor, to the knowledge of the Company, threatened, to which the
Company or any of its subsidiaries is or would be a party or of which any property of the Company or any of its subsidiaries is or would be the subject which, if determined adversely to the Company or any of its subsidiaries, would individually or
in the aggregate have a material adverse effect on the current or future financial position, shareholders’ equity or results of operations of the Company and its subsidiaries or on the power or ability of the Company to perform its obligations
under this Agreement, the Indenture or the Securities or to consummate the transactions contemplated herein and therein; 

  

	 	(q)	The Company and its subsidiaries (i) are in compliance with any and all applicable foreign federal, state and local laws and regulations relating to the protection
of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required
permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a
whole; 

  
 4 

  

	 	(r)	There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up,
closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material
adverse effect on the Company and its subsidiaries, taken as a whole; 

  

	 	(s)	When the Securities are issued and delivered pursuant to this Agreement, the Securities will not be of the same class (within the meaning of Rule 144A under the Act) as
securities which are listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in a U.S. automated inter-dealer quotation system; 

 

	 	(t)	The Company is subject to Section 13 or 15(d) of the Exchange Act; 

  

	 	(u)	The Company is not, and after giving effect to the offering and sale of the Securities and the application of the net proceeds thereof, will not be an “investment
company”, as such term is defined in the United States Investment Company Act of 1940, as amended (the “Investment Company Act”); 

  

	 	(v)	Neither the Company, any of its affiliates nor any person acting on its or their behalf has offered or sold the Securities by means of any general solicitation or
general advertising within the meaning of Rule 502(c) under the Act; 

  

	 	(w)	Within the preceding six months, neither the Company, any of its affiliates nor any other person acting on its or their behalf has offered or sold to any person any
Securities, or any securities of the same or a similar class as the Securities, other than Securities offered or sold to the Purchaser hereunder. The Company will take reasonable precautions designed to insure that any offer or sale, direct or
indirect, in the United States or to any U.S. person (as defined in Rule 902 under the Act) of any Securities or any substantially similar security issued by the Company, within six months subsequent to the date on which the distribution of the
Securities has been completed (as notified to the Company by the Purchaser), is made under restrictions and other circumstances reasonably designed not to affect the status of the offer and sale of the Securities in the United States and to U.S.
persons contemplated by this Agreement as transactions exempt from the registration provisions of the Act; 

  

	 	(x)	KPMG LLP, which has audited certain financial statements of the Company and its subsidiaries and has audited the Company’s internal control over financial
reporting, is an independent registered public accounting firm as required by the Act and the rules and regulations of the Commission thereunder; 

  

	 	(y)	It is not necessary in connection with the offer, sale and delivery of the Securities to the Purchaser in the manner contemplated by this Agreement to register the
Securities under the Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended; 

  

	 	(z)	The Company and its subsidiaries have and will maintain insurance covering their respective properties, operations, personnel and businesses, which insurance is in
amounts and insures against such losses and risks, in each case as the Company believes is in accordance with customary industry practice for companies of similar size and operations, except where the failure to maintain such insurance would not,
singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; 

  

	 	(aa)	 The Company and each of its subsidiaries possess all licenses, certificates, approvals and permits issued by, and has made all declarations and filings
with, the appropriate federal, state or foreign regulatory agencies or bodies (including, without limitation, the Federal Food and Drug Administration, the Federal Drug Enforcement Administration and comparable state agencies) necessary for the
ownership of the Company’s and its subsidiaries’ properties or the conduct of its and their businesses (including, without limitation, the marketing of the products that the Company and its subsidiaries currently market) as described in
the Pricing Circular, except 

  
 5 

	 	 
where the failure to possess or make the same would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole; and none of the Company
or its subsidiaries have received notification of any revocation or modification of any such license, certificate, authorization or permit where the revocation or modification would result in a material adverse effect on the Company and its
subsidiaries, taken as a whole, or have any reason to believe that any such license, certificate, authorization or permit will not be renewed where the failure to renew would have a material adverse effect on the Company and its subsidiaries, taken
as a whole; 

  

	 	(bb)	The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) of the Exchange Act) that complies with the
requirements of the Exchange Act and has been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting is effective and the Company is not aware of any material
weaknesses in its internal control over financial reporting; 

  

	 	(cc)	Since the date of the latest audited financial statements included or incorporated by reference in the Pricing Circular, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and 

 

	 	(dd)	The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) of the Exchange Act) that comply with the requirements of the
Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and principal financial officer
by others within those entities; and such disclosure controls and procedures are effective. 

  

	2.	Subject to the terms and conditions herein set forth, the Company agrees to issue and sell to the Purchaser, and the Purchaser agrees to purchase from the Company, at a
purchase price of 98.00% of the principal amount thereof, the Firm Securities. 

 The Company hereby grants to the
Purchaser the right to purchase at its election up to $30,000,000 aggregate principal amount of Optional Securities, at the purchase price for the Firm Securities set forth in the first paragraph of this Section 2. Any such election to purchase
Optional Securities may be exercised in whole or from time to time in part by written notice from you to the Company, setting forth the aggregate principal amount of Optional Securities to be purchased and the date on which such Optional Securities
are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in Section (4) hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than ten business days
after the date of such notice. 
  

	3.	Upon the authorization by you of the release of the Securities, the Purchaser proposes to offer the Securities for sale upon the terms and conditions set forth in this
Agreement and the Offering Circular and the Purchaser hereby represents and warrants to, and agrees with, the Company that: 

  

	 	(a)	It will offer and sell the Securities only to persons who it reasonably believes are “qualified institutional buyers” (“QIBs”) within the meaning of
Rule 144A under the Act in transactions meeting the requirements of Rule 144A; 

  

	 	(b)	It is an institutional accredited investor as set forth in subsections (1), (2), (3) or (7) of Rule 501(a) under the Act; and 

 

	 	(c)	It will not offer or sell the Securities by any form of general solicitation or general advertising, including but not limited to the methods described in Rule 502(c)
under the Act. 

  
 6 

  

	4.    (a)	The Securities to be purchased by the Purchaser hereunder will be represented by one or more definitive global Securities in book-entry form which will be deposited by
or on behalf of the Company with The Depository Trust Company (“DTC”) or its designated custodian. The Company will deliver the Securities to the Purchaser against payment by the Purchaser of the purchase price therefor by wire transfer to
an account designated by the Company in Federal (same day) funds, by causing DTC to credit the Securities to the account of the Purchaser. The Company will cause the certificates representing the Securities to be made available for checking at least
twenty-four hours prior to the Time of Delivery (as defined below) at the office of Cleary Gottlieb Steen & Hamilton LLP, One Liberty Plaza, New York, NY 10006 (the “Closing Location”). The time and date of such delivery and
payment shall be 9:30 a.m., New York City time, on August 4, 2008 or such other time and date as the Purchaser and the Company may agree upon in writing and, with respect to the Optional Securities, 9:30 a.m., New York City time, on the date
specified in the written notice given by the Purchaser of its election to purchase such Optional Securities, or such other time and date as the Purchaser and the Company may agree upon in writing, provided that any Subsequent Time of Delivery (as
defined below), if any, shall not be more than 30 calendar days from and including the First Time of Delivery (as defined below). The time and date for delivery of the Firm Securities is herein called the “First Time of Delivery”, the time
and date for delivery of any Optional Securities, if not the First Time of Delivery, is herein called the “Subsequent Time of Delivery”, and each such time and date for delivery is herein called a “Time of Delivery”.

  

	 	(b)	The documents to be delivered at the Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including the cross-receipt for the
Securities and any additional documents requested by the Purchaser pursuant to Section 8(l) hereof, will be delivered at such time and date at the Closing Location, and the Securities will be delivered at the office of DTC or its designated
custodian, all at the Time of Delivery. A meeting will be held at the Closing Location at 5:00 p.m., New York City time, on the New York Business Day next preceding the Time of Delivery, at which meeting the final drafts of the documents to be
delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section 4, “New York Business Day” shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not
a day on which banking institutions in New York are generally authorized or obligated by law or executive order to close. 

  

	5.	The Company agrees with the Purchaser: 

  

	 	(a)	To prepare the Preliminary Offering Circular and the Offering Circular in a form approved by you; to make no amendment or any supplement to the Offering Circular to
which you have not consented promptly after reasonable notice thereof; and to furnish you with copies thereof; 

  

	 	(b)	Promptly from time to time to take such action as you may reasonably request to qualify the Securities and the shares of Stock issuable upon conversion of the
Securities for offering and sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to
complete the distribution of the Securities, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction;

  

	 	(c)	To furnish the Purchaser with written and electronic copies of the Preliminary Offering Circular and the Offering Circular and each amendment and supplement thereto in
such quantities as you may from time to time reasonably request, and if, at any time prior to the expiration of nine months after the date of the Offering Circular, any event shall have occurred as a result of which the Offering Circular as then
amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Offering
Circular is delivered, not misleading, or, if for any other reason it shall be necessary or desirable during such same period to amend or supplement the Offering Circular, to notify you and upon your request to prepare and furnish without charge to
the Purchaser and to any dealer in securities as many written and electronic copies as you may from time to time reasonably request of an amended Offering Circular or a supplement to the Offering Circular which will correct such statement or
omission or effect such compliance; 

  
 7 

  

	 	(d)	During the period beginning from the date hereof and continuing until the date 90 days after the date hereof, not to offer, sell contract to sell or otherwise dispose
of, except as provided hereunder any securities of the Company that are substantially similar to the Securities or the Stock, including but not limited to any securities that are convertible into or exchangeable for, or that represent the right to
receive, Stock or any such substantially similar securities (other than pursuant to equity compensation plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of this Agreement),
without your prior written consent; 

  

	 	(e)	Not to be or become, at any time prior to the expiration of three years after the latest Time of Delivery, an open-end investment company, unit investment trust,
closed-end investment company or face-amount certificate company that is or is required to be registered under Section 8 of the Investment Company Act; 

 

	 	(f)	At any time when the Company is not subject to Section 13 or 15(d) of the Exchange Act, for the benefit of holders from time to time of Securities, to furnish at
its expense, upon request, to holders of Securities and prospective purchasers of securities information satisfying the requirements of subsection (d)(4)(i) of Rule 144A under the Act (the “Additional Issuer Information”);

  

	 	(g)	If requested by you, to use its best efforts to cause the Securities to be eligible for the PORTAL Market trading system; 

 

	 	(h)	To furnish to the holders of the Securities (such obligation to be satisfied by publicly-available filings with the Commission if the Company is then subject to
Section 13 or 15(d) under the Exchange Act) an annual report (including a balance sheet and statements of income, shareholders’ equity and cash flows of the Company and its consolidated subsidiaries certified by independent public
accountants) and, after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the date of the Offering Circular), to make available to its shareholders consolidated summary financial
information of the Company and its subsidiaries for such quarter in reasonable detail, all in accordance with the timing requirements of the Exchange Act for a company subject to Section 13 or 15(d) under the Exchange Act;

  

	 	(i)	During a period of five years from the date of the Offering Circular, provided that the Securities remain outstanding, to furnish to you copies of all reports or other
communications (financial or other) furnished to shareholders of the Company and copies of any reports and financial statements furnished to or filed with the Commission or any securities exchange on which the Securities or any class of securities
of the Company is listed (such obligations to be satisfied by publicly-available filings with the Commission if the Company is then subject to Section 13 or 15(d) under the Exchange Act); and to deliver to you such additional information
concerning the business and financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its subsidiaries are consolidated
in reports furnished to its shareholders generally or to the Commission), except to the extent the provision of such information would be prohibited by any applicable laws or would require public disclosure thereof pursuant to Regulation FD;

  

	 	(j)	During the period of one year after the latest Time of Delivery, the Company will not, and will not permit any of its affiliates to, resell any of the Securities that
have been reacquired by any of them; 

  

	 	(k)	To use the net proceeds received by it from the sale of the Securities pursuant to this Agreement in the manner specified in the Pricing Circular under the caption
“Use of Proceeds”; 

  
 8 

  

	 	(l)	To reserve and keep available at all times shares of Stock on the same terms as the Company’s authorized and issued common stock, for the purpose of enabling the
Company to satisfy any obligations to issue shares of its Stock upon conversion of the Securities; and 

  

	 	(m)	To use its best efforts to list, subject to notice of issuance, the shares of Stock issuable upon conversion of the Securities on The NASDAQ Global Select Market.

  

	6.    (a)	The Company represents and agrees that, without the prior consent of the Purchaser, it has not made and will not make any offer relating to the Securities that, if the
offering of the Securities contemplated by this Agreement were conducted as a public offering pursuant to a registration statement filed under the Act with the Commission, would constitute an “issuer free writing prospectus,” as defined in
Rule 433 under the Act (any such offer is hereinafter referred to as a “Company Supplemental Disclosure Document”); 

  

	 	(b)	the Purchaser represents and agrees that, without the prior consent of the Company, other than one or more term sheets relating to the Securities containing customary
information and conveyed to purchasers of securities, it has not made and will not make any offer relating to the Securities that, if the offering of the Securities contemplated by this Agreement were conducted as a public offering pursuant to a
registration statement filed under the Act with the Commission, would constitute a “free writing prospectus,” as defined in Rule 405 under the Act (any such offer (other than any such term sheets), is hereinafter referred to as a
“Purchaser Supplemental Disclosure Document”); and 

  

	 	(c)	any Company Supplemental Disclosure Document or Purchaser Supplemental Disclosure Document the use of which has been consented to by the Company and the Purchaser is
listed on Schedule I(b) hereto. 

  

	7.	The Company covenants and agrees with the Purchaser that the Company will pay or cause to be paid the following: (i) the fees, disbursements and expenses of the
Company’s counsel and accountants in connection with the issue of the Securities and the shares of Stock issuable upon conversion of the Securities and all other expenses in connection with the preparation and printing of the Preliminary
Offering Circular and the Offering Circular and any amendments and supplements thereto and the mailing and delivering of copies thereof to the Purchaser and dealers; (ii) the cost of printing or producing this Agreement, the Indenture, the Blue
Sky and Legal Investment Memoranda, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Securities; (iii) all expenses in connection with the
qualification of the Securities and the shares of Stock issuable upon conversion of the Securities for offering and sale under state securities laws as provided in Section 5(b) hereof, including the fees and disbursements of counsel for the
Purchaser in connection with such qualification and in connection with the Blue Sky and legal investment surveys; (iv) any fees charged by securities rating services for rating the Securities; (v) the cost of preparing the Securities;
(vi) the fees and expenses of the Trustee and any agent of the Trustee and the fees and disbursements of counsel for the Trustee in connection with the Indenture and the Securities; (vii) any cost incurred in connection with the
designation of the Securities for trading in PORTAL and the listing of the shares of Stock issuable upon conversion of the Securities; and (viii) all other costs and expenses of the Company incident to the performance of its obligations
hereunder which are not otherwise specifically provided for in this Section. It is understood, however, that, except as provided in this Section and Sections 9 and 11 hereof, the Purchaser will pay all of its own costs and expenses, including the
fees of its counsel, transfer taxes on resale of any of the Securities by it, and any advertising expenses connected with any offers it may make. 

  

	8.	The obligations of the Purchaser hereunder at any Time of Delivery shall be subject, in its discretion, to the condition that all representations and warranties and
other statements of the Company herein are, at and as of such Time of Delivery, true and correct, the condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional
conditions: 

  

	 	(a)	Cleary Gottlieb Steen & Hamilton LLP, counsel for the Purchaser, shall have furnished to you such opinion or opinions, dated such Time of Delivery, with
respect to the matters as you may reasonably request, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters; 

  
 9 

  

	 	(b)    (i)	Alston & Bird LLP, counsel for the Company, shall have furnished to the Purchaser and the Convertible Note Hedge and Warrant Counterparty their written
opinion, dated such Time of Delivery, in form and substance satisfactory to you, to the effect that: 

  

	 	(1)	Gulf South Medical Supply, Inc. is validly existing as a corporation and in good standing under the laws of the State of Delaware; and all of the issued shares of
capital stock of Gulf South Medical Supply, Inc. have been duly and validly authorized and issued, are fully paid and non assessable, and are owned of record by the Company; 

 

	 	(2)	To the knowledge of such counsel, other than as set forth in the Offering Circular, there are no legal or governmental proceedings pending to which the Company or any
of its subsidiaries is a party which seek to restrain, enjoin, prevent the consummation of or otherwise challenge the transactions contemplated hereby or the issuance or sale of the Securities or issuance of the Stock upon conversion of the
Securities; 

  

	 	(3)	The Securities have been duly authorized for issuance under the provisions of the Indenture and when executed by the Company and authenticated by the Trustee in
accordance with the provisions of the Indenture and delivered to and paid for by the Purchaser in accordance with the terms of the Purchase Agreement, will constitute valid and binding obligations of the Company entitled to the benefits provided by
the Indenture, enforceable against the Company in accordance with their terms, subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to
general equitable principles (regardless of whether such enforcement is considered in a proceeding at law or in equity); and the Securities and the Indenture conform to the descriptions thereof in the Offering Circular; 

 

	 	(4)	Assuming the due authorization, execution, delivery and authentication by the other parties thereto, the Convertible Note Hedge and Warrant Transaction Documentation
and the Indenture constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability
relating to or affecting creditors’ rights and to general equitable principles (regardless of whether such enforcement is considered in a proceeding at law or in equity); 

 

	 	(5)	The issue and sale of the Securities and the execution, delivery and performance by the Company of the Securities, the Indenture and this Agreement and the consummation
of the transactions herein and therein contemplated will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended March 28, 2008, or filed as an exhibit to any subsequently filed Form 10-Q or Form 8-K, nor will such actions result in any
violation of the provisions of any statute, rule or regulation of the State of New York or the United States of America, or the Delaware General Corporation Law, or, to such counsel’s knowledge, any judgment, order or decree binding upon the
Company or any of its subsidiaries or any of their properties; 

  

	 	(6)	 No consent, approval, authorization, registration or qualification of or with any court or governmental agency or body of the State of New York or the
United States of America, or under the Delaware General Corporation Law, is required for the issue and sale of the Securities or the consummation by the Company of the transactions contemplated by this Agreement, the Securities,

  
 10 

	 	 
the Indenture or the Convertible Note Hedge and Warrant Transaction Documentation, except such consents, approvals, authorizations, registrations or qualifications as may be required under state
securities or Blue Sky laws in connection with the purchase and distribution of the Securities by the Purchaser; 

  

	 	(7)	The statements set forth in the Pricing Circular and the Offering Circular under the captions “Description of Notes” and “Description of Capital
Stock”, insofar as they purport to constitute a summary of the terms of the Securities and the Stock, under the caption “Certain United States Federal Tax Considerations”, and under the caption “Plan of Distribution”,
insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair; 

  

	 	(8)	The Exchange Act Reports (other than the financial statements and related schedules therein, as to which such counsel need express no opinion), when they were filed
with the Commission, complied as to form in all material respects with the requirements of the Exchange Act, and the rules and regulations of the Commission thereunder; 

 

	 	(9)	No registration of the Securities under the Act, and no qualification of an indenture under the United States Trust Indenture Act of 1939 with respect thereto, is
required for the offer, sale and initial resale of the Securities by the Purchaser in the manner contemplated by this Agreement; and 

  

	 	(10)	The Company is not, and after giving effect to the offering and sale of the Securities and the application of the net proceeds thereof as described in the Offering
Circular under the caption “Use of Proceeds” will not be, an “investment company”, as such term is defined in the Investment Company Act. 

 Such counsel has no reason to believe that (A) the Pricing Disclosure Package, as of the Applicable Time (other than the financial statements and other financial data therein or omitted therefrom, as
to which such counsel need express no opinion), contained any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; or (B) the Offering Circular and any further amendments or supplements thereto made by the Company prior to the Time of Delivery (other than the financial statements and other financial data therein or omitted therefrom, as to
which such counsel need express no opinion) contained as of its date or contains as of the Time of Delivery an untrue statement of a material fact or omitted or omits, as the case may be, to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. 
 Such counsel may limit its
opinions to the laws of the State of New York, the Delaware General Corporation Law and the federal laws of the United States of America. In rendering such opinions, such counsel may assume any matters governed by the laws of the State of Florida,
and, as to matters of fact, may rely upon certificates of officers of the Company and of governmental officials. 
  

	 	(ii)	Holland & Knight LLP, special counsel for the Company, shall have furnished to the Purchaser and the Convertible Note Hedge and Warrant Counterparty their
written opinion, dated such Time of Delivery, in form and substance satisfactory to you, to the effect that: 

  

	 	(1)	The Company is duly incorporated and validly existing as a corporation and in good standing under the laws of the State of Florida, with the corporate power and
authority to (a) own its properties and conduct its business as described in the Offering Circular and (b) enter into and perform its obligations under this Agreement, the Indenture, and the Convertible Note Hedge and Warrant Transaction
Documentation; 

  
 11 

  

	 	(2)	The Company has authorized capital stock as set forth in the Offering Circular; and the shares of Stock initially issuable upon conversion of the Securities have been
duly and validly authorized and, reserved for issuance and, when issued and delivered in accordance with the provisions of the Securities, will be duly and validly issued and fully paid and non-assessable, and will conform to the description of the
Stock contained in the Offering Circular; 

  

	 	(3)	This Agreement, the Indenture, the Convertible Note Hedge Confirmation and the Warrant Confirmation have been duly authorized, executed and delivered by the Company;

  

	 	(4)	The Securities have been duly authorized and executed by the Company; 

  

	 	(5)	The issue and sale of the Securities and the execution, delivery and performance by the Company of the Securities, the Indenture, this Agreement, the Convertible
Note Hedge Confirmation and Warrant Confirmation and the consummation of the transactions herein and therein contemplated will not result in any violation of the provisions of the Articles of Incorporation or By-laws of the Company, any statute,
rule or regulation of the State of Florida; 

  

	 	(6)	No consent, approval, authorization, registration or qualification of or with any court or governmental agency or body of the State of Florida is required for the issue
and sale of the Securities or the consummation by the Company of the transactions contemplated by this Agreement, the Securities, the Indenture or the Convertible Note Hedge and Warrant Transaction Documentation, except such consents, approvals,
authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Securities by the Purchaser; 

 

	 	(7)	The provisions contained in Section 15.01(c) of the Indenture that restrict the ability of the holder of the Notes to exercise and receive delivery of shares of
common stock, par value $.01 per share, of the Company underlying the Notes are effective, in accordance with the terms of the Notes, to limit the beneficial ownership (for purposes of Article IX of the Company’s Amended and Restated Articles
of Incorporation and Section 607 of the Florida Business Corporation Act) attributable to ownership of the Notes to the limit set forth in such provisions contained in Section 15.01(c) of the Indenture; and 

 

	 	(8)	The provisions contained in Section 8(d) of the Warrant Confirmation that restrict the ability of the Dealer (as defined in the Warrant Confirmation) as holder of
the Warrants (as defined in the Warrant Confirmation) to exercise and receive delivery of shares of common stock, par value $.01 per share, of the Company underlying the Warrants, are effective, in accordance with the terms of the Warrants, to limit
the beneficial ownership (for purposes of Article IX of the Company’s Amended and Restated Articles of Incorporation and Section 607 of the Florida Business Corporation Act) attributable to ownership of the Warrants to the limit set forth
in such provisions contained in Section 8(d) of the Warrant Confirmation. 

 Such counsel may limit its
opinions to the laws of the State of Florida. In rendering such opinions, such counsel may rely as to matters of fact upon certificates of officers of the Company and of governmental officials. 

 

	 	(c)	On the date of the Offering Circular prior to the execution of this Agreement and also at each Time of Delivery, KPMG LLP shall have furnished to you a letter or
letters, dated the respective dates of delivery thereof, in form and substance satisfactory to you, to the effect set forth in Annex I hereto; 

  
 12 

  

	 	(d)	(i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included or incorporated by reference
in the Pricing Circular any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set
forth or contemplated in the Pricing Circular, and (ii) since the respective dates as of which information is given in the Pricing Circular there shall not have been any change in the capital stock or long-term debt of the Company or any of its
subsidiaries or any change, or any development involving a prospective change, in or affecting the general affairs, management, financial position, shareholders’ equity or results of operations of the Company and its subsidiaries, otherwise
than as set forth or contemplated in the Pricing Circular, the effect of which, in any such case described in clause (i) or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the
offering or the delivery of the Securities on the terms and in the manner contemplated in this Agreement and in the Offering Circular; 

  

	 	(e)	On or after the Applicable Time (i) no downgrading shall have occurred in the rating accorded the Company’s debt securities by any “nationally recognized
statistical rating organization”, as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Act, and (ii) no such organization shall have publicly announced that it has under surveillance or review, with possible
negative implications, its rating of any of the Company’s debt securities; 

  

	 	(f)	On or after the Applicable Time there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on
The NASDAQ Global Select Market; (ii) a suspension or material limitation in trading in the Company’s securities on The NASDAQ Global Select Market; (iii) a general moratorium on commercial banking activities declared by either
Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv) the outbreak or escalation of hostilities involving the United States or the
declaration by the United States of a national emergency or war or (v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such
event specified in clause (iv) or (v) in your judgment makes it impracticable or inadvisable to proceed with the offering or the delivery of the Securities on the terms and in the manner contemplated in this Agreement and the Offering
Circular; 

  

	 	(g)	The Securities have been designated for trading on the PORTAL Market; 

  

	 	(h)	The shares of Stock issuable upon conversion of the Securities shall have been duly listed, subject to notice of issuance, on The NASDAQ Global Select Market;

  

	 	(i)	The Purchaser shall have received “lock-up” letters to the effect set forth in Section 5(d) hereof, in form and substance satisfactory to it, from
executive officers and directors of the Company on or prior to the date hereof, and such letters shall be in full force and effect on such Time of Delivery; 

 

	 	(j)	The Indenture shall be executed in a form satisfactory to the Purchaser; and 

 

	 	(k)	The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the Company satisfactory to you as to the
accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to such Time of Delivery, as to the matters
set forth in subsection (d) of this Section and as to such other matters as you may reasonably request. 

  

	9.    (a)	 The Company will indemnify and hold harmless the Purchaser against any losses, claims, damages or liabilities, joint or several, to which the Purchaser
may become subject, under the Act, the Exchange Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon

  
 13 

	 	 
an untrue statement or alleged untrue statement of a material fact contained in the Company’s Current Report on Form 8-K furnished to the Commission on July 23, 2008, any Preliminary
Offering Circular, the Pricing Circular, the Offering Circular, or any amendment or supplement thereto, any Company Supplemental Disclosure Document, or arise out of or are based upon the omission or alleged omission to state therein a material fact
necessary to make the statements therein not misleading, and will reimburse the Purchaser for any legal or other expenses reasonably incurred by the Purchaser in connection with investigating or defending any such action or claim as such expenses
are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or
omission or alleged omission made in any Preliminary Offering Circular, the Pricing Circular, the Offering Circular or any such amendment or supplement, or any Company Supplemental Disclosure Document, in reliance upon and in conformity with written
information furnished to the Company by the Purchaser expressly for use therein. 

  

	 	(b)	The Purchaser will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Act,
the Exchange Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Preliminary
Offering Circular, the Pricing Circular, the Offering Circular, or any amendment or supplement thereto, or any Company Supplemental Disclosure Document, or arise out of or are based upon the omission or alleged omission to state therein a material
fact necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in any Preliminary Offering Circular,
the Pricing Circular, the Offering Circular or any such amendment or supplement, or any Company Supplemental Disclosure Document in reliance upon and in conformity with written information furnished to the Company by the Purchaser expressly for use
therein; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. 

 

	 	(c)	Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if
a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying party shall not relieve it from any
liability which it may have to any indemnified party otherwise than under such subsection. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the
indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who
shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party
shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than
reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action
or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an
unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf of any indemnified
party. 

  

	 	(d)	 If the indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under subsection
(a) or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or

  
 14 

	 	 
payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits
received by the Company on the one hand and the Purchaser on the other from the offering of the Securities. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law or if the indemnified party
failed to give the notice required under subsection (c) above, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company on the one hand and the Purchaser on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well
as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Purchaser on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting
expenses) received by the Company bear to the total underwriting discounts and commissions received by the Purchaser, in each case as set forth in the Offering Circular. The relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Purchaser on the other and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this subsection (d) were
determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the
losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), the Purchaser shall not be required to contribute any amount in excess of the amount by which the total price at which the Securities were
offered to investors exceeds the amount of any damages which the Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. 

 

	 	(e)	The obligations of the Company under this Section 9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same
terms and conditions, to each person, if any, who controls the Purchaser within the meaning of the Act or the Exchange Act; and the obligations of the Purchaser under this Section 9 shall be in addition to any liability which the Purchaser may
otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company and to each person, if any, who controls the Company within the meaning of the Act or the Exchange Act. 

 

	10.	The respective indemnities, agreements, representations, warranties and other statements of the Company and the Purchaser, as set forth in this Agreement or made by or
on behalf of either of them, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of the Purchaser or any controlling person of the
Purchaser, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Securities. 

  

	11.	If for any reason the Securities are not delivered by or on behalf of the Company as provided herein (except for failure of the condition set forth in clauses (i),
(iii), (iv) or (v) of Section 8(f) hereof or default by the Purchaser in its obligation to purchase the Securities), the Company will reimburse the Purchaser for all out of pocket expenses, including fees and disbursements of counsel,
reasonably incurred by the Purchaser in making preparations for the offer, sale, purchase and delivery of the Securities, but the Company shall then be under no further liability to the Purchaser except as provided in Sections 7 and 9 hereof.

  

	12.	All statements, requests, notices and agreements hereunder shall be in writing, and if to the Purchaser shall be delivered or sent by mail, telex or facsimile
transmission to you at 85 Broad Street, 20th Floor, New York, New York 10004, Attention: Registration Department; and if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth in
the Offering Circular, Attention: Chief Financial Officer. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. 

  
 15 

  
 In accordance with the
requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Purchaser is required to obtain, verify and record information that identifies its clients, including the Company, which information may
include the name and address of its clients, as well as other information that will allow the Purchaser to properly identify its clients. 
  

	13.	This Agreement shall be binding upon, and inure solely to the benefit of, the Purchaser, the Company and, to the extent provided in Sections 9 and 10 hereof, the
officers and directors of the Company and each person who controls the Company or the Purchaser, and their respective heirs, executors, administrators, successors and assigns, and except as set forth in Section 5(f), no other person shall
acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Securities from the Purchaser shall be deemed a successor or assign by reason merely of such purchase. 

 

	14.	Time shall be of the essence of this Agreement. 

  

	15.	The Company acknowledges and agrees that (i) the purchase and sale of the Securities pursuant to this Agreement is an arm’s-length commercial transaction
between the Company, on the one hand, and the Purchaser, on the other, (ii) in connection therewith and with the process leading to such transaction the Purchaser is acting solely as a principal and not the agent or fiduciary of the Company,
(iii) the Purchaser has assumed no advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether the Purchaser has advised or is currently
advising the Company on other matters) and no other obligation to the Company except the obligations expressly set forth in this Agreement and (iv) the Company has consulted its own legal and financial advisors to the extent it deemed
appropriate. The Company agrees that it will not claim that the Purchaser has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading
thereto. 

  

	16.	This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Purchaser with respect to the subject matter
hereof. 

  

	17.	This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 

 

	18.	The Company and the Purchaser hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby. 

  

	19.	This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such
respective counterparts shall together constitute one and the same instrument. 

  

	20.	Notwithstanding anything herein to the contrary, the Company (and the Company’s employees, representatives, and other agents) are authorized to disclose to any and
all persons, the tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and structure, without the
Purchaser’s imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to
comply with securities laws. For this purpose, “tax treatment” means U.S. federal and state income tax treatment, and “tax structure” is limited to any facts that may be relevant to that treatment. 

  
 16 

  
 [Remainder of this
page intentionally left blank] 

  
 17 

  
 Exhibit 10.3

 EXECUTION VERSION 
 If the foregoing is in accordance with your understanding, please sign and return to us four counterparts hereof, and upon the acceptance hereof by you, this letter and such acceptance hereof shall
constitute a binding agreement between the Purchaser and the Company. 
  

			
	Very truly yours,
	
	PSS World Medical, Inc.
		
	By:	 	/s/ David M. Bronson
		 	Name: David M. Bronson
		 	Title: Executive Vice President and CFO

 Accepted as
of the date hereof: 
  

	
	Goldman, Sachs & Co.
	
	/s/ Goldman, Sachs & Co.
	(Goldman, Sachs & Co.)

  
 SCHEDULE I

  

	(a)	Additional Documents Incorporated by Reference: None. 

  

	(b)	Approved Supplemental Disclosure Documents: 

  

	 	(i)	Company Supplemental Disclosure Documents 

  

	 	1.	8-K dated July 28, 2008 

  

	 	2.	Investor Presentation dated July 29, 2008 

  

	 	(ii)	Purchaser Supplemental Disclosure Documents: None. 

  
 A-19

  
 SCHEDULE II

 Final Pricing Term Sheet 
  

			
	Issuer:	  	PSS World Medical, Inc. (NASDAQ: PSSI) (the “Company”) 3.125%
		
	Issue:	  	Convertible Senior Notes due 2014 (the “Notes”)
		
	Aggregate Principal Amount:	  	$200,000,000
		
	Over-allotment Option:	  	$30,000,000
		
	Offering Price:	  	99.50% of the principal amount of the Notes, plus accrued interest, if any, from the Settlement Date
		
	Interest Rate:	  	3.125% per annum
		
	Interest Payment Dates:	  	February 1 and August 1 of each year, beginning on February 1, 2009
		
	Maturity:	  	2014
		
	Reference Price:	  	$16.64, the last reported sale price for the Company’s common stock on the NASDAQ Global Select Market on July 29, 2008
		
	Conversion Premium:	  	Approximately 27.5% over the reference price
		
	Conversion Price:	  	Approximately $21.22, subject to adjustment
		
	Conversion Rate:	  	47.1342 shares of common stock per $1,000 principal amount of Notes, subject to adjustment
		
	Fundamental Change Permits Holders to Require the Company to Repurchase the Notes:	  	If the Company undergoes a “fundamental change” (as defined in the Preliminary Offering Memorandum under “Description of Notes – Fundamental Change Permits
Holders to Require Us to Repurchase Notes”), each holder of the Notes will have the option to require the Company to repurchase all or any portion of such holder’s Notes. The fundamental change repurchase price will be 100% of the amount
of the Notes to be repurchased plus any accrued and unpaid interest.
		
	Ranking:	  	The Notes will be the Company’s senior unsecured obligations and will rank equally with all of its existing and future senior debt and senior to any of its subordinated
debt. The Notes will be structurally subordinated to all existing and future liabilities of the Company’s subsidiaries and will be effectively subordinated to any existing and future secured indebtedness, including secured indebtedness under
the Company’s credit facility. As of March 28, 2008, the Company had $480 million aggregate principal amount of indebtedness and other liabilities outstanding.

  
 A-20

			
	Use of Proceeds:	  	The Company estimates that the net proceeds to it from this offering will be $195 million (or approximately $225 million if Goldman, Sachs & Co. exercises in full its option
to purchase additional Notes), after payment of Goldman, Sachs & Co.’s discounts and estimated offering expenses to be paid by the Company. The Company intends to use a portion of the net proceeds of this offering to repurchase, repay or
redeem its 2.25% Convertible Senior Notes due March 15, 2024 on or before their next redemption date on March 15, 2009 and to use a portion of the net proceeds to repurchase approximately 2.1 million shares of its common stock at an
aggregate purchase price of approximately $35 million in negotiated transactions with institutional investors concurrently with this offering. The Company also intends to use approximately $25 million (or approximately $28.7 million if Goldman,
Sachs & Co. exercises in full its option to purchase additional Notes) of the net proceeds of this offering and of the proceeds of the warrant transactions described in the Preliminary Offering Memorandum to pay the cost of the convertible note
hedge transactions. Remaining proceeds, if any, will be used for general corporate purposes.
		
	Sole Book-Running Manager:	  	Goldman, Sachs & Co.
		
	Trade Date:	  	July 29, 2008
		
	Settlement Date:	  	August 4, 2008
		
	Listing:	  	None
		
	Additional Information:	  	Goldman, Sachs & Co. inadvertently purchased 300,000 shares of the Company’s common stock at an average price of approximately $16.86 per share between 3:48 and 3:50
p.m. on July 29, 2008.
		
	CUSIP:	  	69366A AC4
		
	ISIN:	  	US69366AAC45
		
	Purchase of convertible note hedge and sale of warrants:	  	The convertible note hedges will cover, subject to customary anti-dilution adjustments, approximately 9,426,840 shares of the Company’s common stock (or approximately
10,840,866 shares if Goldman, Sachs & Co. exercises in full its option to purchase additional Notes). The warrants will cover, subject to customary anti-dilution adjustments, approximately 9,426.840 shares of the Company’s common stock (or
approximately 10,840,866 shares if Goldman, Sachs & Co. exercises in full its option to purchase additional Notes).

  
 A-21

			
	Adjustment to Shares Delivered upon Conversion in Connection with a Fundamental Change:	  	The following table sets forth the adjustments to the conversion rate, expressed as a number of additional shares to be received per $1,000 in principal amount of the Notes, in
the event of a fundamental change (as defined in the Preliminary Offering Memorandum (as defined below)):

  

																															
	 	 	  	Make-Whole Reference Date	 
	Stock
Price	 	  	August 4,
2008	 	  	August 1,
2009	 	  	August 1,
2010	 	  	August 1,
2011	 	  	August 1,
2012	 	  	August 1,
2013	 	  	August 1,
2014	 
	$	16.64	  	  	 	12.9619	  	  	 	12.9619	  	  	 	12.9619	  	  	 	12.9619	  	  	 	12.9619	  	  	 	12.9619	  	  	 	12.9619	  
	$	18.00	  	  	 	11.3378	  	  	 	10.6216	  	  	 	10.0166	  	  	 	9.4890	  	  	 	8.9221	  	  	 	8.4213	  	  	 	8.4213	  
	$	19.00	  	  	 	10.2745	  	  	 	9.5364	  	  	 	8.8744	  	  	 	8.2432	  	  	 	7.5094	  	  	 	6.5622	  	  	 	5.4973	  
	$	20.00	  	  	 	9.3669	  	  	 	8.6188	  	  	 	7.9196	  	  	 	7.2164	  	  	 	6.3664	  	  	 	5.2028	  	  	 	2.8658	  
	$	22.00	  	  	 	7.9118	  	  	 	7.1684	  	  	 	6.4377	  	  	 	5.6596	  	  	 	4.6914	  	  	 	3.3284	  	  	 	0.0000	  
	$	24.00	  	  	 	6.8093	  	  	 	6.0911	  	  	 	5.3655	  	  	 	4.5733	  	  	 	3.5863	  	  	 	2.2276	  	  	 	0.0000	  
	$	26.00	  	  	 	5.9541	  	  	 	5.2714	  	  	 	4.5714	  	  	 	3.7994	  	  	 	2.8479	  	  	 	1.5924	  	  	 	0.0000	  
	$	30.00	  	  	 	4.7289	  	  	 	4.1272	  	  	 	3.5030	  	  	 	2.8145	  	  	 	1.9939	  	  	 	1.0063	  	  	 	0.0000	  
	$	35.00	  	  	 	3.7371	  	  	 	3.2312	  	  	 	2.7062	  	  	 	2.1334	  	  	 	1.4761	  	  	 	0.7420	  	  	 	0.0000	  
	$	40.00	  	  	 	3.0735	  	  	 	2.6473	  	  	 	2.2069	  	  	 	1.7312	  	  	 	1.1976	  	  	 	0.6157	  	  	 	0.0000	  
	$	45.00	  	  	 	2.5970	  	  	 	2.2350	  	  	 	1.8621	  	  	 	1.4620	  	  	 	1.0172	  	  	 	0.5309	  	  	 	0.0000	  
	$	50.00	  	  	 	2.2365	  	  	 	1.9256	  	  	 	1.6063	  	  	 	1.2646	  	  	 	0.8849	  	  	 	0.4656	  	  	 	0.0000	  
	$	60.00	  	  	 	1.7224	  	  	 	1.4864	  	  	 	1.2449	  	  	 	0.9858	  	  	 	0.6954	  	  	 	0.3684	  	  	 	0.0000	  
	$	75.00	  	  	 	1.2317	  	  	 	1.0668	  	  	 	0.8985	  	  	 	0.7167	  	  	 	0.5095	  	  	 	0.2715	  	  	 	0.0000	  
	$	90.00	  	  	 	0.9143	  	  	 	0.7940	  	  	 	0.6719	  	  	 	0.5393	  	  	 	0.3860	  	  	 	0.2069	  	  	 	0.0000	  
	$	120.00	  	  	 	0.5309	  	  	 	0.4620	  	  	 	0.3935	  	  	 	0.3193	  	  	 	0.2318	  	  	 	0.1261	  	  	 	0.0000	  
	$	150.00	  	  	 	0.3148	  	  	 	0.2733	  	  	 	0.2333	  	  	 	0.1907	  	  	 	0.1403	  	  	 	0.0777	  	  	 	0.0000	  

 The exact stock prices and make-whole
reference dates may not be set forth in the table above, in which case: 
  

	 	•	 	 If the stock price is between two stock price amounts in the table or the make-whole reference date is between two dates in the table, the number of
additional shares will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock price amounts and the two dates, as applicable, based on a 365-day year.

  

	 	•	 	 If the stock price is greater than $150.00 per share, subject to adjustment, no adjustments will be made to the base conversion rate.

  

	 	•	 	 If the stock price is less than $16.64 per share, subject to adjustment, no adjustments will be made to the base conversion rate.

 Notwithstanding the foregoing, in no event will the conversion rate be increased to more than 60.0961 shares of common
stock per $1,000 in principal amount of Notes pursuant to this provision, subject to adjustment from time to time as set forth in the Preliminary Offering Memorandum. 

  
 A-22

  
 This communication is intended for the
sole use of the person to whom it is provided by the sender. 
 These securities have not been registered under the Securities Act of 1933, as
amended (the “Securities Act”), and may only be sold to qualified institutional buyers pursuant to Rule 144A of the Securities Act or pursuant to another applicable exemption from registration. 

This term sheet relates only to the Notes described herein and should be read together with the Company’s Preliminary Offering Memorandum dated
July 28, 2008 (including the documents incorporated by reference therein) relating to the Notes (the “Preliminary Offering Memorandum”) before making a decision in connection with an investment in the Notes. The information in this
term sheet supersedes the information in the Company’s Preliminary Offering Memorandum to the extent that it is inconsistent therewith. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary
Offering Memorandum. 
 ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE
DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. 

  
 A-23

  
 ANNEX I

 Pursuant to Section 8(c) of the Purchase Agreement, the accountants shall furnish letters to the Purchasers to the effect that:

  

	(i)	They are an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities Exchange Act of 1934
(the “Exchange Act”) and the applicable published rules and regulations thereunder adopted by the Securities and Exchange Commission and the Public Accounting Oversight Board (United States); 

 

	(ii)	In their opinion, the consolidated financial statements and financial statement schedules audited by them and included or incorporated by reference in the Preliminary
Offering Circular and the Offering Circular comply as to form in all material respects with the applicable requirements of the Exchange Act and the related published rules and regulations; 

 

	(iii)	The selected financial information with respect to the consolidated results of operations and financial position of the Company for the five most recent fiscal years
included or incorporated by reference in the Preliminary Offering Circular and the Offering Circular agrees with the corresponding amounts (after restatements where applicable) in the audited consolidated financial statements for such five fiscal
years; 

  

	(iv)	On the basis of limited procedures not constituting an audit in accordance with generally accepted auditing standards, consisting of a reading of the unaudited
financial statements and other information referred to below, a reading of the latest available interim financial statements of the Company and its subsidiaries, inspection of the minute books of the Company and its subsidiaries since the date of
the latest audited financial statements included or incorporated by reference in the Preliminary Offering Circular and the Offering Circular, inquiries of officials of the Company and its subsidiaries responsible for financial and accounting matters
and such other inquiries and procedures as may be specified in such letter, nothing came to their attention that caused them to believe that: 

  

	 	(A)	as of a specified date not more than five days prior to the date of such letter, there have been any changes in the consolidated capital stock or any increase in the
consolidated long-term debt of the Company and its subsidiaries, or any decreases in consolidated net current assets or shareholders’ equity or other items specified by the Purchaser, or any increases in any items specified by the Purchaser, in
each case as compared with amounts shown in the latest balance sheet included or incorporated by reference in the Preliminary Offering Circular and the Offering Circular except in each case for changes, increases or decreases which the Preliminary
Offering Circular and the Offering Circular discloses have occurred or may occur or which are described in such letter; 

  

	 	(E)	for the period from the date of the latest financial statements included or incorporated by reference in the Preliminary Offering Circular and the Offering Circular to
the specified date referred to in clause (D) there were any decreases in consolidated net sales or in the total or per-share amounts of income before extraordinary items or in net income or other items specified by the Purchaser, or any
increases in any items specified by the Purchaser, in each case as compared with the comparable period of the preceding year and with any other period of corresponding length specified by the Purchaser, except in each case for decreases or increases
which the Preliminary Offering Circular and the Offering Circular discloses have occurred or may occur or which are described in such letter; and 

  

	(v)	 In addition to the examination referred to in their report(s) included or incorporated by reference in the Preliminary Offering Circular and the
Offering Circular and the limited procedures, inspection of minute books, inquiries and other procedures referred to in paragraphs (iii) and (iv) above, they have carried out certain specified procedures, not constituting an audit

  
 A-24

	 	 
in accordance with generally accepted auditing standards, with respect to certain amounts, percentages and financial information specified by the Purchaser, which are derived from the general
accounting records of the Company and its subsidiaries, which appear in the Preliminary Offering Circular and the Offering Circular, and have compared certain of such amounts, percentages and financial information with the accounting records of the
Company and its subsidiaries and have found them to be in agreement. 

  
 A-25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]